Dear Editor, Valproic acid is a mood stabilizer used in bipolar disorder (1). As a result of its use, nausea, vomiting, diarrhea, constipation, and elevated liver enzymes can be seen (2). Development of thrombocytopenia is more probable than leukopenia, anemia, and pancytopenia, which are rare hematological side effects (3).
the result of bone marrow suppression by VPA. In our case, a 58-year-old male patient had thrombocytopenia and anemia due to the use of valproic acid. In the literature, among hematological side effects, thrombocytopenia is frequently reported due to the use of VPA but there is insufficient knowledge about thrombocytopenia with anemia. In the current case, the hematological side effects of VPA were evaluated.
A 58-year-old male patient feeling stronger had increased spend of money, paranoia and persecutive delusions, decreased sleep, increased psychomotor activity and aggressiveness for one month. He had a cerebrovascular accident 8 years previously and showed aggression and quietness. His blood tests, cranial CT and MR were normal and he was hospitalized as having mania.
He was given valproic acid 1000 mg and risperidone 2 mg per day. As his motility, increased speech and agitation continued, the risperidone dose was increased to 4 mg/ day. In the first week of hospitalization, blood VPA was 60 so VPA was increased to 1500 mg/day. Due to development of Parkinsonism and audio-visual delusions, risperidone was discontinued and olanzapine 5 mg/day was initiated.
A repeat of his cranial MR was again normal. As his aggressiveness increased, the olanzapine dose was increased to 20 mg gradually. In the second week of treatment, thrombocytopenia (platelets: 68000) was seen and acetylsalicylicacid and VPA were discontinued, while treatment with 20 mg per day olanzapine was continued.
VPA level with its use of 1500 mg/day was 104.2. In the third week, together with thrombocytopenia, the hemoglobin level decreased to 13.2 g/dl. In the 4th and 5th weeks of treatment, motility, speech and agitation decreased and the thrombocyte level increased, but the tendency of decrease in hemoglobin level (12 g/dl)
continued. There were no other reasons for the etiology of anemia. In the 7 th week, hematological levels and clinical signs and symptoms were normal so the patient was discharged. There was no hematological pathology during 12.0 g/dl, which later returned to normal levels. Although thrombocytopenia due to use of VPA is frequently observed, in the literature anemia is reported rarely (8, 9) . In one study, use of valproic acid led to a 9-fold increase in the development of aplastic anemia (10).
Moreover, thrombocytopenia and neutropenia due to use of olanzapine was also previously reported. 
